Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25133541 | 0.90 | GNAO1 (0.36) | ACHEGNAO1SIGMAR1HTR4GBA1 | |
| SCHEMBL25133546 | 0.90 | GNAO1 (0.36) | ACHEGNAO1SIGMAR1HTR4GBA1 | |
| SCHEMBL25133540 | 0.90 | GNAO1 (0.36) | ACHEGNAO1SIGMAR1HTR4GBA1 | |
| SCHEMBL23919055 | 0.87 | CACNA2D1 (0.40) | ACHEGNAO1CHRM5ADRA2CHTR4 | |
| SCHEMBL23919065 | 0.84 | GNAO1 (0.43) | ACHEGNAO1CHRM5ADRA2CSIGMAR1 | |
| SCHEMBL25133512 | 0.84 | CHRM5 (0.42) | ACHEGNAO1CHRM5ADRA2CHTR4 | |
| SCHEMBL25133082 | 0.84 | SIGMAR1 (0.36) | SIGMAR1GBA1 | |
| SCHEMBL26972273 | 0.83 | ACHE (0.42) | ACHECHRM5ADRA2C | |
| SCHEMBL24079231 | 0.83 | GNAO1 (0.36) | GNAO1SIGMAR1ALDH1A1HTT | |
| SCHEMBL1104721 | 0.82 | SIGMAR1 (0.44) | CHRM5ADRA2CSIGMAR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | ACHE 2845/4885GNAO1 3206/4885CHRM5 4497/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | ACHE 2086/4885GNAO1 2111/4885CHRM5 3757/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | ACHE 2845/4885GNAO1 3206/4885CHRM5 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.